Centrexion stock hits 52-week low at $0.77 amid market challenges

Published 10/03/2025, 21:02
Centrexion stock hits 52-week low at $0.77 amid market challenges

In a challenging market environment, Centrexion Therapeutics Corp’s stock has touched a 52-week low, with shares plummeting to $0.77. According to InvestingPro data, this represents a dramatic fall from the 52-week high of $2.75, though analysts maintain price targets ranging from $4 to $10. The biopharmaceutical company, which focuses on developing therapies for chronic pain management, has faced significant headwinds over the past year, reflected in a substantial 1-year change with a decline of -31.68%. While the company maintains a strong liquidity position with a current ratio of 36.91 and more cash than debt on its balance sheet, investors have shown concern as the stock struggles to regain momentum, marking a concerning period for the company amidst a broader industry downturn. The current price level represents a critical juncture for Centrexion as it navigates through a phase of investor skepticism and market volatility. For deeper insights into Centrexion’s financial health and additional analysis, investors can access more than 10 exclusive ProTips on InvestingPro.

In other recent news, Context Therapeutics has announced the appointment of Andy Pasternak as its new Chairman of the Board of Directors. Pasternak, bringing over 25 years of biopharmaceutical experience, succeeds Richard Berman. His previous roles include a significant position as Executive Vice President and Chief Strategy Officer at Horizon Therapeutics (NASDAQ:HZNP). In addition to this leadership change, JMP Securities has initiated coverage on Context Therapeutics with a Market Outperform rating, setting a price target of $4.00. This rating highlights the company’s focus on developing next-generation T cell engaging bispecific antibody treatments for solid tumors. Context Therapeutics is actively working on therapies targeting specific antigens such as Claudin 6, Mesothelin, and Nectin-4. The company is refining its therapeutic approach, potentially using these therapies alone or in combination with other treatments. These recent developments underscore Context Therapeutics’ ongoing efforts in the biopharmaceutical sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.